

Structural basis of Zika virus methyltransferase inhibition by sinefungin

Kamil Hercik¹ · Jiri Brynda¹ · Radim Nencka¹ · Evzen Boura¹ 

Received: 5 January 2017 / Accepted: 22 February 2017 / Published online: 29 March 2017
© Springer-Verlag Wien 2017

Abstract Zika virus is considered a major global threat to human kind. Here, we present a crystal structure of one of its essential enzymes, the methyltransferase, with the inhibitor sinefungin. This structure, together with previously solved structures with bound substrates, will provide the information needed for rational inhibitor design. Based on the structural data we suggest the modification of the adenine moiety of sinefungin to increase selectivity and to covalently link it to a GTP analogue, to increase the affinity of the synthesized compounds.

Zika virus has recently emerged as a significant threat to human health in our globalized society [1–3]. This member of the *Flaviviridae* family, genus *Flavivirus*, belongs a group of arthropod-borne viruses that are transmitted mainly by the bite of the *Aedes spp.* mosquitoes [4, 5]. However, sexual transmission [6, 7] and mother-to-fetus transmissions [8] have also been reported, which seem to be especially important because of the linkage between Zika virus infections and birth defects, namely microcephaly [9, 10]. Coupled with the fact that Zika virus RNA can be detected in semen for as long as six months [11], infection with Zika virus may present a serious threat to the safety of human reproduction. Apart from microcephaly and other common symptoms such as fever, rash and joint

pain, Guillain-Barré syndrome was also reported to be associated with Zika virus infection [12]. Guillain-Barré syndrome is a serious condition characterized by rapidly progressing symmetrical muscle weakness. So far, neither a treatment nor vaccine against Zika virus is in clinical use, although significant effort has been invested into this challenging task within the last year [13–18].

As with other members of the *Flavivirus* genus, Zika virus is an enveloped single stranded positive sense RNA (+RNA) virus [19] whose genome contains a methylated cap at its 5' end. This RNA molecule, after simple host cell-associated processing [20], serves as the mRNA for translation of a single large viral polyprotein, which is subsequently cleaved by both cellular and viral proteases into three structural (envelope, E; membrane precursor, PrM; and capsid C) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [21, 22]. The central protein of flavivirus replication is NS5, which is responsible for two distinct catalytic activities. Its first domain (approximately one third of the NS5 protein) is a methyltransferase (MTase) and the second domain is an RNA-dependent RNA polymerase (RdRp) [23].

The vast majority of cellular mRNAs possess a stabilizing cap structure at the 5' end which usually consists of *N*-7-methylguanosine triphosphate combined with 2'-*O*-methylation [24] of the first one or two nucleotides (Fig. 1) [25]. Numerous viruses, including flaviviruses, have developed their own capping mechanisms in order to bypass host innate immunity, enhance the translation process and mimic host mRNA [26]. Apart from the installation of the guanosine triphosphate (Gppp) on the 5' end of the RNA, the methylation of position *N*-7 of Gppp and 2'-*O*-hydroxyl of the following nucleotide(s) is essential for the whole capping process. In humans, the methyl groups are installed in the nucleus by two distinct enzymes (*N*-7

✉ Radim Nencka
nencka@uochb.cas.cz

✉ Evzen Boura
boura@uochb.cas.cz

¹ Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic




Fig. 1 The cap structure consisting of 7-N-methylated guanosine 5'-triphosphate and 2'-O-methyladenosine

MTase and 2'-O-MTase), however, Zika virus MTase catalyzes both methylation steps [27]. The methylation of the cap structure is essential for the whole replication process of flaviviruses, including Zika virus, and its inhibition leads to arrest of viral replication in cells [28]. Therefore, the MTase is one promising target for the discovery and development of novel therapeutic agents against Zika virus infection. We note some compounds targeting Zika virus MTase have already been reported based on an *in silico* screen [29].

Here we report the crystal structure of the Zika virus methyltransferase in complex with pan-methyltransferase inhibitor sinefungin, an adenosine derivative, originally isolated from *Streptomyces griseoleus* by Eli Lilly and Co. as a potential antifungal antibiotic [30]. From a mechanistic point of view, it competes with S-adenosyl-1-methionine (SAM), the natural substrate of numerous MTases [31], and, therefore, presents an interesting starting point for the development of novel competitive inhibitors of this essential enzyme involved in the Zika virus replication cycle.

The last few months have resulted in a frenetic struggle for the structural characterization of the Zika virus proteins, which resulted in the successful crystallization of proteins including Zika virus MTase [32–34]. However, this structure together with an inhibitor was not elucidated until now.

The sequence encoding the Zika virus methyltransferase from ZIKV virus (strain MR766) infected cells was amplified using primers: 5'-GAGGGATCCGGGGGTGGAACGGGAGAGAC-3' (forward) and 5'-GAGGCGGCCG

CCTATTACCGCGTGCCAGAGCCGAGATT-3' (reverse). The coding sequence was cloned into the pHis2 plasmid previously modified to encode an N-terminal 8xHis tag followed by the SUMO protein (a gift from Dr. Ren, Berkeley). The protein was expressed in *E. coli* Rosetta Gami B (DE3) cells in auto-induction medium supplemented with 100 µg/ml ampicillin and 34 µg/ml chloramphenicol using standard protocols [35–37] and subsequently purified using metal affinity chromatography followed by TEV cleavage and size exclusion chromatography using standard methods [38, 39]. Briefly, the cells were lysed by French pressure cell press in lysis buffer (500 mM NaCl, 50 mM Tris pH 8.0, 3 mM 2-mercaptoethanol, 10% glycerol, 5 mM MgCl₂, 0.5 U/ml Salt Active Nuclease [ArcticZymes]) and centrifuged. The supernatant was incubated with Ni-NTA agarose (Machery-Nagel) and subsequently washed with the lysis buffer. The protein was eluted with lysis buffer supplemented with 300 mM imidazole. The 8xHis-SUMO tag was removed by Ulp1 protease cleavage at 4° C overnight and the protein was further purified using size exclusion chromatography on a Superdex 75 column (GE Healthcare). Finally, the protein was concentrated to 10 mg/ml and stored at -80° C until needed.

For crystallization trials sinefungin (Sigma-Aldrich), at a final concentration of 1 mM, was added to purified Zika virus MTase. Diffraction quality crystals grew within two weeks in hanging drops created by mixing 2 µl of the protein with 2 µl of the well solution (100 mM sodium acetate pH 4.6, 39% (v/v) PEG 400). The crystals were flash frozen in liquid nitrogen and data were collected using a home source. The crystals belonged to the monoclinic C2 spacegroup and diffracted to 1.95 Å resolution. The structure was solved by molecular replacement using Zika methyltransferase bound to S-adenosylmethionine (PDB ID: 5KQR) as a search model using Phaser [40] and further refined using the Phenix package [41] to $R_{\text{work}} = 22.67\%$ and $R_{\text{free}} = 26.88\%$ and good stereochemistry as detailed in Table 1. The data and the model were deposited on the PDB database (<http://www.rcsb.org>) under deposition ID 5MRK.

Our crystals contained two Zika virus MTase molecules in their asymmetric unit. We traced the whole polypeptide except for the first four N-terminal residues in both molecules; however, we found the segment Arg37 – His53 disordered only in molecule B. This was probably caused by crystal packing; however, it still reveals that this segment is flexible, as reported by others [34, 42]. The overall fold from our structural analysis of Zika virus MTase is in good accordance with previously solved substrate-bound structures. The MTase domain is composed of eight α -helices and seven β -sheets (Fig. 2A). The β -sheet is mixed (parallel and antiparallel sheets are present) and forms a

Table 1 Statistics of crystallographic data collection and refinement

Data collection	
Crystal	MT + sinefungin
Space group	C2
Cell dimension	a = 144.8 Å, b = 52.0 Å, c = 84.2 Å, $\alpha = 90^\circ$ $\beta = 107.6^\circ$ $\gamma = 90^\circ$
X-ray source	Home source
Wavelength, Å	1.5419
Resolution, Å	29.67 - 1.9 (1.97 - 1.9)
No. of unique reflections	46804 (4328)
I/ σ (I)	11.01 (0.7)
R _{merge} , %	12.4 (160.5)
C _{1/2} , %	99.5 (38.2)
Data completeness, %	98.67 (92.06)
Multiplicity	5.18
Refinement	
R _{work} , %	22.67
R _{free} , %	26.88
rms bond angle deviation, °	0.005
rms bond angle deviation, Å	0.72
Ramachandran (outliers/ favored)	0%/97.8%

central motif from $\beta 3$ to $\beta 6$. The *S*-adenosyl methionine (SAM) binding subdomain is defined by sheets $\beta 3$, $\beta 2$, $\beta 1$, and $\beta 4$ and helices $\alpha 3$, $\alpha 4$, and $\alpha 5$ while the remaining

sheets ($\beta 5$, $\beta 6$, $\beta 7$) and helices ($\alpha 1$, $\alpha 2$, $\alpha 6$, $\alpha 7$, $\alpha 8$) form the second subdomain. The density for sinefungin was clearly visible upon molecular replacement in both Zika virus MTase molecules and was located in the SAM binding pocket (Fig. 2B, Fig. 3A). It is held in place mainly by hydrogen bonds between sinefungin and residues Ser56, Gly86 and Trp87 (backbone), His110, Glu111, Asp146, Lys105 (backbone), and Asp131 as detailed in Fig. 3B. Comparison with SAM and SAH bound structures reveals that the binding of sinefungin and SAM differs mainly in the conformation of Arg84 and Glu111 (Fig. 3C) while the difference in the SAH bound structure is, again, changed in the conformation of Arg84 and also rather an insignificant change in the position of Ser56 (Fig. 3D).

The goal of this study was to obtain structural information that would be useful for drug design against Zika virus. Superposition of the currently obtained structure with the sinefungin inhibitor in the SAM pocket and previous structures with GTP and 7-methyl-guanosine-5'-diphosphate (m⁷GDP) in the GTP/cap pocket (Fig. 3) reveals two distinct substrate binding sites. One site for SAM or its analogues and a second for GTP (Fig. 3A). Here, we speculate that a sub-nanomolar inhibitor of the Zika virus methyltransferase can be designed by a fragment-connecting approach; specifically, we propose a chimeric molecule that would bind to both the SAM and m⁷GDP binding pockets. Both sinefungin and SAM can serve, in principle, as starting molecules. The chiral center in sinefungin is inherently a complication. However, this compound is commercially available and simple synthetic




Fig. 2 Structure of the ZIKV methyltransferase in complex with sinefungin. A) The overall fold. B) The sinefungin molecule in the unbiased Fo-Fc omit map, contoured at 3 sigma. Selected residues are shown and colored according to atoms (color figure online)




Fig. 3 A) Superposition of the sinefungin bound structure with previously solved GTP bound (pdb id: 5GOZ) and 7-methylguanosine-5'-diphosphate (pdb id: 5KQS) structures. B) Detail of sinefungin bound in the SAM binding pocket. C) Detail of SAM binding (prepared according to pdb id: 5KQR). D) Detail of SAH

bound in the SAM binding pocket (prepared according to pdb id: 5GOZ). For figures B-D the important residues are shown in stick representation and colored according to elements, hydrogen bonds are drawn as dashed black lines (color figure online)

approaches were reported [43]. To increase selectivity we propose to modify the adenine nucleobase because this approach was shown to be feasible in the development of dengue virus methyltransferase inhibitors [44]. The presented crystal structure shows that the Zika virus MTase possesses a similar lipophilic cavity which can be exploited in order to generate inhibitors specific for viral methyltransferases only.

Zika virus has been identified as a potential threat for human reproduction, especially due to its persistence in semen, putative sexual transmission and teratogenic defects associated with the viral infection during pregnancy [45]. Since there is no treatment for Zika virus infection, the design and development of novel strategies to fight this dangerous pathogen are of imminent importance. We report on a crystal structure of Zika virus methyltransferase in complex with sinefungin, a competitive

methyltransferase inhibitor. The presented data can serve as a useful starting point for the further design of novel inhibitors of Zika virus replication. In particular, we conclude that covalently connecting sinefungin with a GTP or GDP analogue using an appropriate linker will result in outstanding affinity towards this protein, and, together with an increase in selectivity via proper substitution of the nucleobase, will result in highly potent and selective inhibitors of Zika virus replication.

Acknowledgements The Project was also supported by Project InterBioMed LO1302 from Ministry of Education of the Czech Republic, the support of the Academy of Sciences of the Czech Republic (RVO: 61388963) is also acknowledged.

Compliance with ethical standards

Conflict of interests The authors declare no conflict of interests.

References

- Petersen LR, Jamieson DJ, Powers AM, Honein MA (2016) Zika virus. *N Engl J Med* 374(16):1552–1563. doi:10.1056/NEJMr1602113
- Rajah MM, Pardy RD, Condotta SA, Richer MJ, Sagan SM (2016) Zika virus: emergence, phylogenetics, challenges, and opportunities. *Acs Infect Dis* 2(11):763–772. doi:10.1021/acsinfectdis.6b00161
- Barzon L, Trevisan M, Sinigaglia A, Lavezzo E, Palu G (2016) Zika virus: from pathogenesis to disease control. *FEMS Microbiol Lett.* doi:10.1093/femsle/fwv202
- Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, Shi PY, Vasilakis N (2016) Zika virus: history, emergence, biology, and prospects for control. *Antiviral Res* 130:69–80. doi:10.1016/j.antiviral.2016.03.010
- Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, Dupont-Rouzeyrol M, Lourenco-de-Oliveira R, Failloux AB (2016) Differential Susceptibilities of *Aedes aegypti* and *Aedes albopictus* from the Americas to Zika Virus. *Plos Negl Trop Dis.* doi:10.1371/journal.pntd.0004543
- Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau V (2015) Potential sexual transmission of zika virus. *Emerg Infect Dis* 21(2):359–361. doi:10.3201/eid2102.141363
- Hills SL, Russell K, Hennessey M, Williams C, Oster AM, Fischer M, Mead P (2016) Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—Continental United States. *Mmwr* 65(8):215–216
- Fiorentino DG, Montero FJ (2016) The Zika virus and pregnancy. *Curr Obstet Gynecol Rep* 5(3):234–238. doi:10.1007/s13669-016-0171-1
- Schuler-Faccini L, Ribeiro EM, Feitosa IML, Horovitz DDG, Cavalcanti DP, Pessoa A, Doriqui MJR, Neri JI, Neto JMD, Wanderley HYC, Cernach M, El-Husny AS, Pone MVS, Seroa CLC, Sanseverino MTV, Brazilian Med Genet Soc Zika E (2016) Possible Association Between Zika Virus Infection and Microcephaly—Brazil, 2015. *Mmwr* 65(3):59–62
- Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, Kolenc M, Rus KR, Vipotnik TV, Vodusek VF, Vizjak A, Pizem J, Petrovec M, Zupanc TA (2016) Zika virus associated with microcephaly. *N Engl J Med* 374(10):951–958. doi:10.1056/NEJMoa1600651
- Nicastrì E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G (2016) Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. *Eurosurveillance* 21(32):6–9. doi:10.2807/1560-7917.es.2016.21.32.30314
- Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, Neil J, Ghawche F (2016) Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet* 387(10027):1531–1539. doi:10.1016/S0140-6736(16)00562-6
- Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJF, Neyts J (2016) The Viral polymerase inhibitor 7-deaza-2'-C-methyladenosine Is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. *PLoS Negl Trop Dis.* doi:10.1371/journal.pntd.0004695
- Hercík K, Kozak J, Šála M, Dejmeš M, Hřebabečý H, Zborníková E, Smola M, Ruzek D, Nencka R, Boura E (2016) Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase. *Antiviral Res* 137:131–133. doi:10.1016/j.antiviral.2016.11.020
- Eyer L, Nencka R, Huvarova I, Palus M, Alves MJ, Gould EA, De Clercq E, Ruzek D (2016) Nucleoside inhibitors of Zika virus. *J Infect Dis* 214(5):707–711. doi:10.1093/infdis/jiw226
- Lei J, Hansen G, Nitsche C, Klein CD, Zhang LL, Hilgenfeld R (2016) Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. *Science* 353(6298):503–505. doi:10.1126/science.aag2419
- Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Munoz G, McGrath EL, Urrabaz-Garza R, Gao JL, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA (2016) A screen of FDA-approved drugs for inhibitors of Zika virus infection. *Cell Host Microbe* 20(2):259–270. doi:10.1016/j.chom.2016.07.004
- Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, Shi PY, Qin CF (2016) Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus. *Open Forum Infect Dis.* doi:10.1093/ofid/ofw175
- Kuno G, Chang GJJ (2007) Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. *Adv Virol* 152(4):687–696. doi:10.1007/s00705-006-0903-z
- Funk A, Truong K, Nagasaki T, Torres S, Floden N, Melian EB, Edmonds J, Dong HP, Shi PY, Khromykh AA (2010) RNA structures required for production of subgenomic flavivirus RNA. *J Virol* 84(21):11407–11417. doi:10.1128/jvi.01159-10
- Sironi M, Forni D, Clerici M, Cagliani R (2016) Nonstructural proteins are preferential positive selection targets in Zika virus and related flaviviruses. *Plos Negl Trop Dis.* doi:10.1371/journal.pntd.0004978
- Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren JS, Selisko B, Sponeri S, Steuber H, Stuart DJ, Unge T, Bolognesi M (2010) Structure and functionality in flavivirus NS-proteins: perspectives for drug design. *Antiviral Res* 87(2):125–148. doi:10.1016/j.antiviral.2009.11.009
- Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B (2002) An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. *EMBO J* 21(11):2757–2768. doi:10.1093/emboj/21.11.2757
- Dong H, Chang DC, Hua MH, Lim SP, Chionh YH, Hia F, Lee YH, Kukkaro P, Lok SM, Dedon PC, Shi PY (2012) 2'-O methylation of internal adenosine by flavivirus NS5 methyltransferase. *PLoS Pathog* 8(4):e1002642. doi:10.1371/journal.ppat.1002642
- Langberg SR, Moss B (1981) Post-transcriptional modifications of mRNA. Purification and characterization of cap I and cap II RNA (nucleoside-2'-)-methyltransferases from HeLa cells. *J Biol Chem* 256(19):10054–10060
- Dong HP, Zhang B, Shi PY (2008) Flavivirus methyltransferase: a novel antiviral target. *Antiviral Res* 80(1):1–10. doi:10.1016/j.antiviral.2008.05.003
- Dong HP, Fink K, Zust R, Lim SP, Qin CF, Shi PY (2014) Flavivirus RNA methylation. *J Gen Virol* 95:763–778. doi:10.1099/vir.0.062208-0
- Brecher M, Chen H, Liu B, Banavali NK, Jones SA, Zhang J, Li Z, Kramer LD, Li H (2015) Novel broad spectrum inhibitors targeting the flavivirus methyltransferase. *PLoS One.* doi:10.1371/journal.pone.0130062
- Stephen P, Baz M, Boivin G, Lin SX (2016) Structural insight into NS5 of Zika virus leading to the discovery of MTase inhibitors. *J Am Chem Soc* 138(50):16212–16215. doi:10.1021/jacs.6b10399
- Hamil RL, Hoehn MM (1973) A9145, a new adenine-containing antifungal antibiotic. I. Discovery and isolation. *J Antibiot (Tokyo)* 26(8):463–465

31. Zhang J, Zheng YG (2016) SAM/SAH analogs as versatile tools for SAM-dependent methyltransferases. *ACS Chem Biol* 11(3):583–597. doi:[10.1021/acscchembio.5b00812](https://doi.org/10.1021/acscchembio.5b00812)
32. Coloma J, Jain R, Rajashankar KR, Garcia-Sastre A, Aggarwal AK (2016) Structures of NS5 methyltransferase from Zika virus. *Cell Rep* 16(12):3097–3102. doi:[10.1016/j.celrep.2016.08.091](https://doi.org/10.1016/j.celrep.2016.08.091)
33. Zhang C, Feng T, Cheng J, Li Y, Yin X, Zeng W, Jin X, Li Y, Guo F, Jin T (2016) Structure of the NS5 methyltransferase from Zika virus and implications in inhibitor design. *Biochem Biophys Res Commun*. doi:[10.1016/j.bbrc.2016.11.098](https://doi.org/10.1016/j.bbrc.2016.11.098)
34. Coutard B, Barral K, Lichiere J, Selisko B, Martin B, Aouadi W, Lombardia MO, Debart F, Vasseur JJ, Guillemot JC, Canard B, Decroly E (2017) Zika virus methyltransferase: structure and functions for drug design perspectives. *J Virol*. doi:[10.1128/JVI.02202-16](https://doi.org/10.1128/JVI.02202-16)
35. Studier FW (2005) Protein production by auto-induction in high-density shaking cultures. *Protein Expr Purif* 41(1):207–234. doi:[10.1016/j.pep.2005.01.016](https://doi.org/10.1016/j.pep.2005.01.016)
36. Baumlova A, Chalupska D, Rozycki B, Jovic M, Wisniewski E, Klima M, Dubankova A, Kloer DP, Nencka R, Balla T, Boura E (2014) The crystal structure of the phosphatidylinositol 4-kinase IIalpha. *EMBO Rep* 15(10):1085–1092. doi:[10.15252/embr.201438841](https://doi.org/10.15252/embr.201438841)
37. Mejdrova I, Chalupska D, Kogler M, Sala M, Plackova P, Baumlova A, Hrebabecky H, Prochazkova E, Dejmek M, Guillon R, Strunin D, Weber J, Lee G, Birkus G, Mertlikova-Kaiserova H, Boura E, Nencka R (2015) Highly selective phosphatidylinositol 4-kinase IIIbeta inhibitors and structural insight into their mode of action. *J Med Chem* 58(9):3767–3793. doi:[10.1021/acs.jmedchem.5b00499](https://doi.org/10.1021/acs.jmedchem.5b00499)
38. Rezaczkova L, Boura E, Herman P, Vecer J, Bourova L, Sulc M, Svoboda P, Obsilova V, Obsil T (2010) 14-3-3 protein interacts with and affects the structure of RGS domain of regulator of G protein signaling 3 (RGS3). *J Struct Biol* 170(3):451–461. doi:[10.1016/j.jsb.2010.03.009](https://doi.org/10.1016/j.jsb.2010.03.009)
39. Klima M, Toth DJ, Hexnerova R, Baumlova A, Chalupska D, Tykvar J, Rezaczkova L, Sengupta N, Man P, Dubankova A, Humpolickova J, Nencka R, Veverka V, Balla T, Boura E (2016) Structural insights and in vitro reconstitution of membrane targeting and activation of human PI4KB by the ACBD3 protein. *Sci Rep* 6:23641. doi:[10.1038/srep23641](https://doi.org/10.1038/srep23641)
40. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. *J Appl Crystallogr* 40(pt 4):658–674. doi:[10.1107/S0021889807021206](https://doi.org/10.1107/S0021889807021206)
41. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66(Pt 2):213–221. doi:[10.1107/S0907444909052925](https://doi.org/10.1107/S0907444909052925)
42. Jansson AM, Jakobsson E, Johansson P, Lantze V, Coutard B, de Lamballerie X, Unge T, Jones TA (2009) Structure of the methyltransferase domain from the Modoc virus, a flavivirus with no known vector. *Acta Crystallogr D Biol Crystallogr* 65(pt 8):796–803. doi:[10.1107/S0907444909017260](https://doi.org/10.1107/S0907444909017260)
43. Barton DHR, Gero SD, Quicletsire B, Samadi M (1991) Expedient synthesis of natural (S)-sinefungin and of its C-6' epimer. *J Chem Soc Perk T* 1(5):981–985. doi:[10.1039/p19910000981](https://doi.org/10.1039/p19910000981)
44. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, Zou G, Monaghan P, Chung KY, Dong HP, Liu BP, Bodenreider C, Lee G, Ding M, Chan WL, Wang G, Jian YL, Chao AT, Lescar J, Yin Z, Vedananda TR, Keller TH, Shi PY (2011) Small molecule inhibitors that selectively block dengue virus methyltransferase. *J Biol Chem* 286(8):6233–6240. doi:[10.1074/jbc.M110.179184](https://doi.org/10.1074/jbc.M110.179184)
45. Franca GV, Schuler-Faccini L, Oliveira WK, Henriques CM, Carmo EH, Pedi VD, Nunes ML, Castro MC, Serruya S, Silveira MF, Barros FC, Victora CG (2016) Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. *Lancet* 388(10047):891–897. doi:[10.1016/S0140-6736\(16\)30902-3](https://doi.org/10.1016/S0140-6736(16)30902-3)